Collplant Biotechnologies LTD 20-F annual reports
The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.
NASDAQ
CollPlant Biotechnologies reports a $11.5 million net loss for 2025, driven by R&D investments and cost-cutting, while advancing rhCollagen-based products and securing new funding.
NASDAQ
20-F: CollPlant Biotechnologies Reports Annual Results, Highlights Progress in Regenerative Medicine
CollPlant Biotechnologies Ltd. releases its annual report for the year ended December 31, 2024, showcasing advancements in its rhCollagen-based regenerative and aesthetic medicine programs.
NASDAQ
20-F: CollPlant Biotechnologies Reports FY2023 Results, Highlights Progress in Regenerative Medicine
CollPlant Biotechnologies reports FY2023 results, highlighting a $10 million milestone payment from AbbVie and advancements in 3D-bioprinted breast implants.